If you have been reading about Cardarine and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
==== Qatar ==== In March 2018 American Republican fundraiser Elliott Broidy filed a lawsuit against Qatar, alleging that Qatar's government stole and leaked his emails in order to discredit him because he was viewed "as an impediment to their plan to improve the country's standing in Washington." In May 2018, the lawsuit named Mohammed bin Hamad bin Khalifa Al Thani, brother of the Emir of Qatar, and his associate Ahmed Al-Rumaihi, as allegedly orchestrating Qatar's cyber warfare campaign against Broidy. Further litigation revealed that the same cybercriminals who targeted Broidy had targeted as many as 1,200 other individuals, some of whom are also "well-known enemies of Qatar" such as senior officials of the U.A.E., Egypt, Saudi Arabia, and Bahrain. While these hackers almost always obscured their location, some of their activity was traced to a telecommunication network in Qatar.
=== Re–Ru === Lynne Regan (Ph.D. 1987). British biochemist and biotechnologist at the University of Edinburgh which studies interactions between proteins and nucleic acids. Jens Reich (b. 1939). German biophysicist at the Central Institute of Molecular Biology of the Academy of Sciences in Berlin-Buch, pioneer in systems biology. Founder of the New Forum (civil rights movement). Jacques Ricard (1929–2018). French biochemist at the Institut Jacques Monod known for studies of plant enzymes and for developing the concept of enzyme memory. David Rittenberg (1906–1970). American biochemist at Columbia, a pioneer in the use of radioactive tracers to study metabolism. Member Natl. Acad. Sci. USA. Alexander Rich (1924–2015). American biophysicist at MIT, whose many contributions included elucidation of the structure of collagen (with Francis Crick). Member Natl. Acad. Sci. USA. Jane S. Richardson (b. 1941). American biophysicist at Duke University, known for the ribbon diagram, a method of representing the 3D structures of proteins. Member Natl. Acad. Sci. USA. Thorburn Brailsford Robertson (1884–1930), Australian physiologist and biochemist, known for promoting the use of insulin for diabetes in Australia. Dame Carol V. Robinson (b. 1956), British chemist and mass spectroscopist at the University of Oxford known for studies of protein folding. Robert G. Roeder (b. 1942), American biochemist, pioneer in eukaryotic transcription. Irwin Rose (1926–2015). American biochemist at the University of Pennsylvania, noted for the discovery of ubiquitin-mediated protein degradation.
== Pulsed SILAC == Pulsed SILAC (pSILAC) is a variation of the SILAC method where the labelled amino acids are added to the growth medium for only a short period of time. This allows monitoring differences in de novo protein production rather than raw concentration.
=== Development === The series was announced by JioHotstar in early 2024, following the popularity of other Tamil web series such as Mathagam and Label. It was slated to be a medical drama titled Heart Beat, written and directed by Deepak Sundarrajan, and produced by Padmini Velu and Rajavelu for A Tele Factory.
== Applications == Because all primordial bismuth is bismuth-209, bismuth-209 is used for all normal applications of bismuth, such as being used as a replacement for lead, in cosmetics, in paints, and in several medicines such as Pepto-Bismol. Alloys containing bismuth-209 such as bismuth bronze have been used for thousands of years.
Sources: en.wikipedia.org
LRP5 may be essential for the development of retinal vasculature, and may play a role in capillary maturation. Mutations in this gene also cause familial exudative vitreoretinopathy. A glial-derived extracellular ligand, Norrin, acts on a transmembrane receptor, Frizzled4, a coreceptor, Lrp5, and an auxiliary membrane protein, TSPAN12, on the surface of developing endothelial cells to control a transcriptional program that regulates endothelial growth and maturation. LRP5 knockout in mice led to increased plasma cholesterol levels on a high-fat diet because of the decreased hepatic clearance of chylomicron remnants. When fed a normal diet, LRP5-deficient mice showed a markedly impaired glucose tolerance with marked reduction in intracellular ATP and Ca2+ in response to glucose, and impairment in glucose-induced insulin secretion. IP3 production in response to glucose was also reduced in LRP5—islets possibly caused by a marked reduction of various transcripts for genes involved in glucose sensing in LRP5—islets. LRP5-deficient islets lacked the Wnt-3a-stimulated insulin secretion. These data suggest that WntLRP5 signaling contributes to the glucose-induced insulin secretion in the islets. In osteoarthritic chondrocytes the Wnt/beta-catenin pathway is activated with a significant up-regulation of beta-catenin mRNA expression. LRP5 mRNA and protein expression are also significantly up-regulated in osteoarthritic cartilage compared to normal cartilage, and LRP5 mRNA expression was further increased by vitamin D.
== Biology and genetics == S. boulardii was originally described as a species distinct from S. cerevisiae based on phenotypic traits, including the inability to ferment galactose, a reported lack of sporulation under standard laboratory conditions, and increased tolerance to human body temperature, gastric acidity, and digestive enzymes compared with many S. cerevisiae strains. Subsequent molecular and genomic analyses, however, have shown that S. boulardii falls within the genetic diversity of S. cerevisiae, forming a distinct clade most closely related to wine-associated strains. Like other S. cerevisiae strains, S. boulardii possesses 16 nuclear chromosomes and a 2-micron plasmid, and is diploid, carrying genetic determinants for both mating types (MATa and MATα). However, the MATa locus in S. boulardii contains mutations predicted to impair mating and sporulation, which may account for its reduced or absent sporulation phenotype under laboratory conditions. S. boulardii shares with other S. cerevisiae strains the production of secreted proteins reported to interfere with certain bacterial pathogens and their toxins, including a 63-kDa phosphatase (Pho8) that reduces Escherichia coli endotoxin activity and a 54-kDa serine protease (Ysp3) capable of degrading Clostridioides difficile toxins A and B. An additional, as-yet-unidentified protein of approximately 120 kDa has been reported to inhibit cholera toxin–induced increases in intracellular cyclic AMP (cAMP).
Polymyalgia rheumatica (PMR) is a systemic inflammatory disease characterized by pain or stiffness, usually in the neck, shoulders, upper arms, and hips, but which may occur all over the body. Almost all cases occur in people age 50 or older. Pain and stiffness of PMR is worse in the morning and improves throughout the day, but these symptoms frequently persist to some extent throughout the day and into the evening. People who have polymyalgia rheumatica may also have temporal arteritis (giant cell arteritis), an inflammation of blood vessels in the face which can cause blindness if not treated quickly. The pain and stiffness can result in a lowered quality of life, and can lead to depression. The exact cause of PMR, including whether or not it may be an autoimmune disease, is unclear. Persons of Northern European descent are at greater risk. There is no definitive laboratory test, but C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) can be useful as non-specific markers of systemic inflammation. PMR is usually treated with corticosteroids taken by mouth. Most people need to continue the corticosteroid treatment for two to three years. PMR sometimes goes away on its own in a year or two, but medications and self-care measures (e.g., eating the recommended amount of fruits and vegetables) can improve the rate of recovery. PMR was first established as a distinct disease in 1966 by a case report on 11 patients at Mount Sinai Hospital in New York City. It takes its name from the Greek word Πολυμυαλγία polymyalgia, which means "pain in many muscles".
Specifically when set up in a loop with a buffering liquid between the incoming and outgoing fluid running in a circuit, and with active transport pumps on the outgoing fluid's tubes, the system is called a countercurrent multiplier, enabling a multiplied effect of many small pumps to gradually build up a large concentration in the buffer liquid. Other countercurrent exchange circuits where the incoming and outgoing fluids touch each other are used for retaining a high concentration of a dissolved substance or for retaining heat, or for allowing the external buildup of the heat or concentration at one point in the system. Countercurrent exchange circuits or loops are found extensively in nature, specifically in biologic systems. In vertebrates, they are called a rete mirabile, originally the name of an organ in fish gills for absorbing oxygen from the water. It is mimicked in industrial systems. Countercurrent exchange is a key concept in chemical engineering thermodynamics and manufacturing processes, for example in extracting sucrose from sugar beet roots. Countercurrent multiplication is a similar but different concept where liquid moves in a loop followed by a long length of movement in opposite directions with an intermediate zone. The tube leading to the loop passively building up a gradient of heat (or cooling) or solvent concentration while the returning tube has a constant small pumping action all along it, so that a gradual intensification of the heat or concentration is created towards the loop.
=== Optical isomerism === Glutamic acid is chiral; two mirror-image enantiomers exist: d(−), and l(+). The l form is more widely occurring in nature, but the d form occurs in some special contexts, such as the bacterial capsule and cell walls of bacteria (which produce it from the l form with the enzyme glutamate racemase) and can be found in small amounts in the liver and other organs of mammals, either directly from dietary sources or from production by the gut microbiota.
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.